Martha Buitrago, MD
Infectious Disease · Idaho Falls, IDNPI 1356349492
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by AbbVie at 44.9% of the total. Reporting peaked in 2022 at $60 and has fallen 69.3% since, to $19 in 2024.
Across 7 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$63
- La Jolla Pharmaceutical Company$43
- Tetraphase Pharmaceuticals, Inc.$18
- Insmed, Inc.$15
Across 645 payments — averaging $2698.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1M
- Janssen Research & Development, LLC$454K
- Sanofi Pasteur Inc.$246K
- AstraZeneca$12K
- Eli Lilly$506
What the payments were for
- Food & beverage$139100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $63 |
| La Jolla Pharmaceutical Company | 2 | $43 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $15 |
How this compares
$139 in reported general payments places this provider in the 55th percentile of 29 infectious disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 32 | $127,485 |
| ErtapenemErtapenem Sodium | 35 | $23,209 |
| Daptomycin | 62 | $22,012 |
| Doxycycline Hyclate | 119 | $7,412 |
| Cephalexin | 93 | $5,693 |
| CeftriaxoneCeftriaxone Sodium | 17 | $4,584 |
| Meropenem | 28 | $4,270 |
| Rifampin | 27 | $3,782 |
| Gentamicin Sulfate | 14 | $3,199 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 13 | $2,871 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 44 | $2,184 |
| Doxycycline Monohydrate | 26 | $1,943 |
| Sodium Chloride0.9 % Sodium Chloride | 108 | $1,358 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 54 | $1,185 |
| Azithromycin | 11 | $1,031 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Idaho Falls
- Richard NathanIdaho Falls$5K
- John BagwellIdaho Falls$149
- David PomboIdaho Falls$47
- Sean Tristan CookCoeur D Alene$32K
- Sky BlueBoise$2K
- Thomas CoffmanBoise$838
- Sarah ShewayishBoise$769
- Quentin DoperalskiBoise$516
- John HammerBoise$389
- Sharon OsterBoise$327
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.